

In the June 2, 2003 Office Action, the Examiner required restriction under 35 U.S.C. § 121 to one of the following allegedly independent and distinct inventions:

- I. Claims 7-11 and 22, drawn to an isolated polynucleotide encoding a fusion polypeptide, wherein said fusion polypeptide is capable of forming a stable homodimer, classified in class 536, subclass 23.5.
- II. Claims 11 and 19-21 and 23-24, drawn to an isolated polynucleotide encoding a fusion polypeptide, wherein said fusion polypeptide comprises an oligomerization domain that will not bind to itself, classified in class 536, subclass 23.5.

Applicant's undersigned attorney hereby elects Group I claims 7-11 and 22 drawn to an isolated polynucleotide encoding a fusion polypeptide, wherein said fusion polypeptide is capable of forming a stable homodimer.

**SUMMARY**

No additional fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

Respectfully submitted,

June 25, 2003  
Date

Elizabeth Lassen  
Elizabeth Lassen  
Attorney for Applicant  
Registration No. 31,845  
Telephone: (508) 270-2553  
Facsimile: (508) 872-5415

GENZYME CORPORATION  
15 Pleasant Street Connector  
P.O. Box 9322  
Framingham, Massachusetts 01701-9322